Osteoprotegerin (OPG) in chronic kidney disease patients may act as a protective mechanism to compensate for bone turnover effects of renal failure and appears to be a bridge between bone tissue and vascular system [10]. Here, TNFRSF11B is linked to Renal insufficiency.